Clinical Toxicities of Histone Deacetylase Inhibitors
The HDAC inhibitors are a new family of antineoplastic agents. Since the entry of these agents into our therapeutic armamentarium, there has been increasing interest in their use. Although this family comprises chemical compounds from unrelated chemical classes that have different HDAC isoform speci...
Main Authors: | Richard L. Piekarz, John J. Wright, Susan E. Bates, Srividya Subramanian, Igor Espinoza-Delgado |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2010-08-01
|
Series: | Pharmaceuticals |
Subjects: | |
Online Access: | http://www.mdpi.com/1424-8247/3/9/2751/ |
Similar Items
-
Histone deacetylases and their inhibitors: molecular mechanisms and therapeutic implications in diabetes mellitus
by: Xiaojie Wang, et al.
Published: (2012-08-01) -
Histone Deacetylase Inhibitors in the Treatment of Hepatocellular Carcinoma: Current Evidence and Future Opportunities
by: Nikolaos Garmpis, et al.
Published: (2021-03-01) -
Roles of histone deacetylases in epigenetic regulation: emerging paradigms from studies with inhibitors
by: Delcuve Geneviève P, et al.
Published: (2012-03-01) -
The therapeutic potential of class I selective histone deacetylase inhibitors in ovarian cancer
by: Dineo eKhabele
Published: (2014-05-01) -
Histone Deacetylases (HDACs): Evolution, Specificity, Role in Transcriptional Complexes, and Pharmacological Actionability
by: Giorgio Milazzo, et al.
Published: (2020-05-01)